Lineage Cell Therapeutics, Inc.
LCTX- Exchange
- NYSE
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0000876343
No open-market purchases or sales by Lineage Cell Therapeutics, Inc. insiders were filed in the last 90 days; 131 institutions reported holding it in 13F filings for Q2 2026, worth $152.7M in total; no superinvestor holds it.
13F holders, Q1 2025
Institutional positions in Lineage Cell Therapeutics, Inc. as of Mar 31, 2025. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 127
- +3 vs. Q4 2024
- Shares held
- 109.4M
- +2.74M (+2.6%) vs. Q4 2024
- Total value
- $49.7M
- −$3.89M (−7.3%) vs. Q4 2024
- New holders
- 19
- 37 more added
- Sold out
- 16
- 22 more reduced
2 institutions that held it in Q4 2024 haven't filed for Q1 2025 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.
Compare with Q4 2024: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting LCTX on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 131 | $152.7M |
| Q1 2026 | 130 | $176.5M |
| Q4 2025 | 123 | $169.8M |
| Q3 2025 | 112 | $148.6M |
| Q2 2025 | 129 | $88.4M |
| Q1 2025 | 127 | $49.7M |
| Q4 2024 | 126 | $53.8M |
| Q3 2024 | 114 | $85.6M |
| Q2 2024 | 113 | $94.2M |
| Q1 2024 | 116 | $138.3M |
| Q4 2023 | 115 | $82.5M |
| Q3 2023 | 104 | $89.1M |
| Q2 2023 | 107 | $106.6M |
| Q1 2023 | 116 | $104.7M |
| Q4 2022 | 106 | $76.2M |
| Q3 2022 | 104 | $73.1M |
| Q2 2022 | 100 | $102.7M |
| Q1 2022 | 109 | $112.3M |
| Q4 2021 | 124 | $182.0M |
| Q3 2021 | 115 | $191.7M |
| Q2 2021 | 115 | $208.5M |
| Q1 2021 | 102 | $141.8M |
Institutions, Q1 2025
Shares, value and share of portfolio for each institution holding Lineage Cell Therapeutics, Inc.; share changes are against Q4 2024.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| HRT Financial LP | 208,918 | $94.0K | 0.00% | +208,918 | New |
| Two Sigma Advisers, LP | 223,364 | $100.9K | 0.00% | +136,400+156.8% | Added |
| Susquehanna International Group, LLP | 236,109 | $106.6K | 0.00% | +172,795+272.9% | Added |
| Cookson Peirce & Co Inc | 250,000 | $112.9K | 0.01% | +250,000 | New |
| UBS Group AG | 263,917 | $119.3K | 0.00% | +43,029+19.5% | Added |
| Bank of New York Mellon Corp | 337,827 | $152.6K | 0.00% | 00.0% | Unchanged |
| Goldman Sachs Group Inc | 350,103 | $158.1K | 0.00% | −34,963−9.1% | Reduced |
| Squarepoint Ops LLC | 357,772 | $161.6K | 0.00% | +265,771+288.9% | Added |
| Two Sigma Investments, LP | 480,423 | $217.0K | 0.00% | +178,879+59.3% | Added |
| Red Crane Wealth Management, LLC | 495,996 | $224.0K | 0.21% | +155,760+45.8% | Added |
| Charles Schwab Investment Management Inc | 503,193 | $227.2K | 0.00% | +86,970+20.9% | Added |
| Nuveen, LLC | 515,445 | $232.8K | 0.00% | +515,445 | New |
| Royal Bank of Canada | 528,656 | $237.0K | 0.00% | +497,168+1,578.9% | Added |
| JPMorgan Chase & Co | 605,044 | $273.2K | 0.00% | −341,355−36.1% | Reduced |
| Gsa Capital Partners LLP | 936,892 | $423.0K | 0.04% | +528,055+129.2% | Added |
| Morgan Stanley | 968,781 | $437.5K | 0.00% | +308,720+46.8% | Added |
| Northern Trust Corp | 1,539,586 | $695.3K | 0.00% | +265,094+20.8% | Added |
| Renaissance Technologies LLC | 2,291,381 | $1.03M | 0.00% | +8,309+0.4% | Added |
| DAFNA Capital Management LLC | 2,511,374 | $1.13M | 0.32% | 00.0% | Unchanged |
| State Street Corp | 2,650,186 | $1.20M | 0.00% | −24,326−0.9% | Reduced |
| Comerica Bank | 3,000,000 | $1.35M | 0.01% | +2,200,000+275.0% | Added |
| Geode Capital Management, LLC | 4,485,586 | $2.03M | 0.00% | +795,100+21.5% | Added |
| Raffles Associates LP | 5,642,088 | $2.55M | 3.10% | +150,000+2.7% | Added |
| Defender Capital, LLC. | 6,310,873 | $3.16M | 1.24% | +347,525+5.8% | Added |
| Vanguard Group Inc | 8,919,043 | $4.03M | 0.00% | +286,115+3.3% | Added |
| BlackRock, Inc. | 11,453,305 | $5.17M | 0.00% | +1,358,628+13.5% | Added |
| Broadwood Capital Inc | 49,560,992 | $22.4M | 1.81% | +7,894,737+18.9% | Added |
| Perceptive Advisors LLC | 0 | $0 | 0.00% | −7,236,843−100.0% | Sold out |
| Alyeska Investment Group, L.P. | 0 | $0 | 0.00% | −3,947,369−100.0% | Sold out |
| Jacobs Levy Equity Management, Inc | 0 | $0 | 0.00% | −1,033,763−100.0% | Sold out |
| Prescott General Partners LLC | 0 | $0 | 0.00% | −386,000−100.0% | Sold out |
| DCF Advisers, LLC | 0 | $0 | 0.00% | −107,751−100.0% | Sold out |
| Atria Wealth Solutions, Inc. | 0 | $0 | 0.00% | −57,423−100.0% | Sold out |
| United Bank | 0 | $0 | 0.00% | −12,000−100.0% | Sold out |
| Thrivent Financial for Lutherans | 0 | $0 | 0.00% | −10,000−100.0% | Sold out |
| Asset Planning,Inc | 0 | $0 | 0.00% | −2,036−100.0% | Sold out |
| Sugar Maple Asset Management, LLC | 0 | $0 | 0.00% | −1,000−100.0% | Sold out |
| Nelson, Van Denburg & Campbell Wealth Management Group, LLC | 0 | $0 | 0.00% | −300−100.0% | Sold out |
| Coppell Advisory Solutions LLC | 0 | $0 | 0.00% | −63−100.0% | Sold out |
| FLP Wealth Management, LLC | 0 | $0 | 0.00% | −50−100.0% | Sold out |
| Plante Moran Financial Advisors, LLC | 0 | $0 | 0.00% | −2−100.0% | Sold out |
| Lazard Asset Management LLC | 0 | $0 | 0.00% | −148−100.0% | Sold out |
| Simplex Trading, LLC | 0 | $0 | 0.00% | −351−100.0% | Sold out |
| Nuveen Asset Management, LLC | – | – | – | – | Not filed |
| RE Dickinson Investment Advisors, LLC | – | – | – | – | Not filed |